Extended Data Fig. 3: Key biomarker expression by RECIST response and PFS/OS association within treatment groups of IMbrave150. | Nature Medicine

Extended Data Fig. 3: Key biomarker expression by RECIST response and PFS/OS association within treatment groups of IMbrave150.

From: Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Extended Data Fig. 3

a, Expression of ABRS, CD274 and Teff signature score by RECIST response in IMbrave150 Atezo-Bev treatment group (n = 119 biologically independent subjects). Box plots are of log2 gene expression scores for response categories, with two-sided P values from Student t tests. Boxes represent median (middle line) and first/third quartile (bottom and upper lines) values. Box whiskers represent the most extreme values within 150% of the interquartile range. b, KM plots of PFS stratified by ABRS, CD274 or Teff signature high vs low expression (median split) within the Aatezo-Bbev (n = 119 biologically independent subjects) or sorafenib (n = 58 biologically independent subjects) treatment group in IMbrave150. c, KM plots of OS stratified by ABRS, CD274 or Teff signature high vs low expression (median split) within the Aatezo-Bbev (n = 119 biologically independent subjects) or sorafenib (n = 58 biologically independent subjects) treatment group in IMbrave150. 95% confidence intervals are indicated in parentheses.

Back to article page